Last reviewed · How we verify
Dongkook Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
0 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| DKF-306 | DKF-306 | marketed | Other | |||
| DKF-313 | DKF-313 | phase 3 | Unknown | Unknown | Unknown | |
| DKF-MA102 | DKF-MA102 | phase 3 | molecular target | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
- Other · 1
- Unknown · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Abdi Ibrahim Ilac San. ve Tic A.S. · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Beijing Tiantan Hospital · 1 shared drug class
- Bursa Yuksek Ihtisas Training and Research Hospital · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Gloucestershire Hospitals NHS Foundation Trust · 1 shared drug class
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Dongkook Pharmaceutical Co., Ltd.:
- Dongkook Pharmaceutical Co., Ltd. pipeline updates — RSS
- Dongkook Pharmaceutical Co., Ltd. pipeline updates — Atom
- Dongkook Pharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Dongkook Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dongkook-pharmaceutical-co-ltd. Accessed 2026-05-16.